tbuckley/cabot-search huggingface dataset:
Managing FDG PET-positive sarcoidosis: “a riddle wrapped in a mystery inside an enigma”
Authors: Adriane D.M. Vorselaars, Heleen A. Crommelin, Coline H.M. van Moorsel, Jan C. Grutters
Journal: European Respiratory Journal (2015)

We read with interest the correspondence from Mohapatra and colleagues regarding our paper "Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis" [1]. We agree with Mohapatra and colleagues that the term refractory sarcoidosis is still under discussion. We defined refractory sarcoidosis in the methods section as "patients with severe sarcoidosis, unresponsive to first- and second-line treatment, or who have experienced severe side-effects from these agents". Diagnosis of sarcoidosis was made according to American Thoracic Society/European Respiratory Society criteria [2], including biopsy. These criteria also describe exclusion of other differential diagnoses. Using the described definition for refractory sarcoidosis yields a very heterogeneous group of patients, consisting of sarcoidosis patients that need third line immunosuppressive therapies, e.g. biologicals such as infliximab. Considerations in managing FDG PET-positive sarcoidosis with infliximab therapy <http://ow.ly/U0qUr>
Corrigendum to ‘The state of measles and rubella in the WHO European Region, 2013’ [Clin Microbiol Infect 20 (Suppl. 5) (2014), pp. 12–18]
Authors: M. Muscat, A. Shefer, M. Ben Mamou, R. Spataru, D. Jankovic, S. Deshevoy, R. Butler, D. Pfeifer
Journal: Clinical Microbiology and Infection (2014)
Longitudinal Strain as Risk Factor for Outcome in Pediatric Dilated Cardiomyopathy
Authors: Susanna L. den Boer, Gideon J. du Marchie Sarvaas, Liselotte M. Klitsie, Gabriëlle G. van Iperen, Ronald B. Tanke, Willem A. Helbing, Ad P.C.M. Backx, Lukas A.J. Rammeloo, Michiel Dalinghaus, Arend D.J. ten Harkel
Journal: JACC. Cardiovascular imaging (2015)
P0842 : Malachite-I: Phase 3B Trial of ombitasvir/paritaprevir/r and dasabuvir +/− ribavirin or telaprevir + peginterferon/ribavirin in treatment-naïve adults with HCV genotype 1
Authors: B. Conway, E. Janczewska, Y. Luo, M. Curescu, S. Greenbloom, A. Streinu-Cercel, F.A. Caruntu, W. Ghesquiere, B. Knysz, W. Mazur, F. Fuster, A. Motoc, A. Soza, V. Arama, O. Dalgard, D. Sullivan, X. Liu, T. Podsadecki
Journal: Journal of Hepatology (2015)
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Authors: Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher, Qianghu Wang, Erik P Sulman, Sebastian Adeberg, Arend Koch, Ali Fuat Okuducu, Stefanie Brehmer, Jens Schittenhelm, Albert Becker, Benjamin Brokinkel, Melissa Schmidt, Theresa Ull, Konstantinos Gousias, Almuth Friederike Kessler, Katrin Lamszus, Jürgen Debus, Christian Mawrin, Yoo-Jin Kim, Matthias Simon, Ralf Ketter, Werner Paulus, Kenneth D Aldape, Christel Herold-Mende, Andreas von Deimling
Journal: JNCI Journal of the National Cancer Institute (2015)

The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P < .001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.
Unexpected Toxicity of Combination Thalidomide and Interferon Alfa-2a Treatment in Metastatic Renal Cell Carcinoma
Authors: P. D. Nathan, M. E. Gore, T. G. Eisen
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.5.1429 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11870194 Unexpected Toxicity of Combination Thalidomide and Interferon Alfa-2a Treatment in Metastatic Renal Cell Carcinoma P. D. NathanxP. D. NathanSearch for articles by this author , M. E. GorexM. E. GoreSearch for articles by this author , T. G. EisenxT. G. EisenSearch for articles by this author Show More Royal Marsden Hospital, Sutton, Surrey, United Kingdom https://doi.org/10.1200/JCO.2002.20.5.1429 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Association Between Distal Hyperplastic Polyps and Proximal Neoplastic Lesions: A Prospective Study Among 5,613 Subjects
Authors: Martin C.S. Wong, Thomas Y.T. Lam, Jessica Y.L. Ching, Victor C.W. Chan, Jeffrey P. Shum, Siew C. Ng, Sunny H. Wong, Arthur K.C. Luk, Simon S.M. Ng, Justin C.Y. Wu, Francis K.L. Chan, Joseph J.Y. Sung
Journal: Clinical Gastroenterology and Hepatology (2015)
Vascular Effects of Diets, Especially Plant Sterol Ester Consumption⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Tatu A. Miettinen, Helena Gylling
Journal: Journal of the American College of Cardiology (2008)
Abstract 15452: Regulation of Kv11.1 C-terminal Isoform Expression by Branch Point of Intron 9
Authors: Qiuming Gong, Matthew R Stump, Zhengfeng Zhou
Journal: Circulation (2014)

The KCNH2 gene encodes the Kv11.1 potassium channel that conducts the rapidly activating delayed rectifier current in the heart and mutations in KCNH2 cause long QT syndrome type 2 (LQT2). Two Kv11.1 C-terminal isoforms are expressed in the heart. Splicing of KCNH2 intron 9 generates the full-length, functional Kv11.1a isoform, while activation of an alternative polyadenylation site within intron 9 leads to the expression of the non-functional, C-terminally truncated Kv11.1a-USO isoform. Only one-third of KCNH2 pre-mRNA is processed to Kv11.1a in the heart due to inefficient intron 9 splicing. The mechanisms that regulate the alternative processing of KCNH2 intron 9 are not fully understood. In this study, we investigate the role of the branch point at the 3’-splice site of intron 9 in the regulation of Kv11.1 isoform expression. Compared to the consensus sequence, the branch point of KCNH2 intron 9 has one mismatch. To test whether the non-consensus branch point sequence contributes to the inefficient splicing of intron 9, we changed the branch point from CTGAG to the consensus sequence CTGAC in an intron-containing full-length KCNH2 gene construct. RNase protection assay, immunoblot and patch clamp analyses showed that the change to consensus sequence in intron 9 branch point increased the expression of the functional Kv11.1a isoform and concomitantly decreased the expression of the non-functional Kv11.1a-USO isoform, resulting in a significant increase in the Kv11.1 channel current. We also studied the LQT2 branch point mutation IVS9-28A>G. We found that the IVS9-28A>G mutation disrupted normal splicing and resulted in exclusive polyadenylation of intron 9, leading to a complete switch from the functional Kv11.1a isoform to the non-functional Kv11.1a-USO isoform. Our results demonstrate isoform switch as a pathogenic mechanism for the IVS9-28A>G mutation and support the conclusion that the KCNH2 intron 9 branch point plays an important role in regulation of the Kv11.1 C-terminal isoform expression and Kv11.1 channel function.
Voluntary euthanasia is now legal in Quebec, says appeal court
Authors: Owen Dyer
Journal: BMJ (2015)

Quebec’s law permitting assisted dying and voluntary euthanasia is now in force, even though the federal government in Ottawa is still drawing up national legislation on the right to die. Quebec has been allowed to go ahead with its own law after the province’s highest court rejected a challenge led by a physicians’ group and a disabled patient.

Paul Saba and his Coalition of Physicians for Social Justice had persuaded a lower court to put the province’s Dying with Dignity Act on hold, arguing …
Iron deficiency anaemia and febrile convulsions
Authors: W. M Wike, W R Kiser
Journal: BMJ (1996)

herbal medicines are in fact the effects of other herbal material used in error.This type of mistake is typified by the irritatingly common practice of naming vincristine and related anticancer compounds as Vinca alkaloids although they are derived from Catharanthus roseus.Unfortunately, classical taxonomists and phytoanalysts do not have the same glamour and potential to attract money as some other scientists and so are an endangered species.Their demise will result in mistakes more serious than the one in the editorial.
Abstract 11133: The Incidence and Predicting Factors of Heart Failure After First Acute Myocardial Infarction: A Population[[Unable to Display Character: &amp;#8208;]]Based Study in Taiwan
Authors: Cheng-Han Lee, Yi-Heng Li, Ching-Lan Cheng, Jyh-Hong Chen, Yea-Huei Kao Yang
Journal: Circulation (2014)

Background: Early coronary revascularization and medical therapy advancement improve the survival of patients (pts) with acute myocardial infarction (AMI). However, survivors of AMI are at heightened risk of developing heart failure (HF) and there is a paucity of information regarding this issue in Asian countries. This study described the temporal trends in the incidence of HF after the first AMI and the predicting factors of HF development in Taiwan. Methods: We conducted a nationwide population-based cohort study by using 1999 to 2009 National Health Insurance Research Database. Pts aged≧18 years, with no history of HF, who hospitalized with a first AMI between January 2002 and December 2008 were identified and followed up for one year. The primary outcome was HF. We evaluated the incidence of HF during the index hospitalization, 30 days, 6 months, and one year after the discharge. The predicting factors of HF were identified by Cox proportional hazard model. Results: Overall, 42,011 first AMI pts (mean age 64.4 ± 13.8 years; male 75.0%) from 2002 to 2008 were identified. The HF incidence during the index hospitalization was 14.8%. After exclusion of HF during the hospitalization, the overall HF prevalence at 30 days, 6 months, and 1 year was 9.6%, 14.2%, and 16.8%, respectively. The HF prevalence at 1 year declined from 17.9% to 14.9% (p&lt;0.05) from 2002 to 2008. The independent predicting factors of HF after the first AMI were elder age (≧65 years) (adjusted HR 1.81, 95% CI 1.51-2.18), diabetes mellitus (adjusted HR 1.30, 95% CI 1.21-1.41), chronic kidney disease (adjusted HR 1.41, 95% CI 1.20-1.65), use of loop diuretics within 30 days after the discharge (adjusted HR 2.21, 95% CI 2.00-2.43), and recurrent AMI (adjusted HR 2.43, 2.16-2.74). Conclusions: Survivors of AMI without prior HF remain at risk of developing HF in Taiwan and most episodes occur within 6 months after AMI. Five important clinical factors of HF were identified that may help us for risk stratification.
P-028 Role of somatostatin analogues in the treatment of neuroendocrine tumors (NETs), experience of Virgen de las Nieves University Hospital
Authors: C. González-Rivas, L. Castillo, E. González-Flores, J. Ruiz-Vozmediano, L. Ochoa, V. Amezcua, J. Martinez-Galán, J. García-García, C. Sanchez-Toro, J.R. Delgado
Journal: Annals of Oncology (2015)
Adiponectin may inhibit chronic intermittent hypoxia-induced endoplasmic reticulum stress and cell apoptosis in genioglossus
Authors: Xilong Zhang, Hanpeng Huang
Journal: European Respiratory Journal (2013)

Objective To investigate the effects of chronic intermittent hypoxia (CIH) and adoponectin (Ad) supplement on endoplasmic reticulum stress (ERS) and cell apoptosis in genioglossus. Methods Wistar rats were randomly divided into three groups: normal control group (group A), CIH group (group B) and CIH+Ad group (group C) with 10 rats in each. Rats in group A were kept breathing normal air, while rats in both group B and group C received same CIH environment. However, rats in group C was given intravenous Ad supplement. At the end of experiment (day 35), the expression of glucose-regulated protein 78(GRP78), P38, c-Jun NH-terminal kinase (JNK) and C/EBP homologous protein (CHOP) of genioglossus were tested with western blot assay.The cell apoptosis was measured through TUNEL and Annexin V/PI staining. Results Compared with control group, in CIH group the P38 was significantly activated, the expression of GRP78 and CHOP proteins of genioglossus were significantly upregulated, and the rate of cell apoptosis was significantly elevated (all P  0.05). Conclusions CIH could induce ERS and significantly enhance cell apoptosis through ativation of P38-CHOP pathway in genioglossus. Supplement of adiponectin could attenuate excessive ERS, inhibit activation of P38-CHOP pathway, and thus further reduce the rate of cell apoptosis in genioglossus.
Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions
Authors: S. C. Wong, R. Dobie, M. A. Altowati, G. A. Werther, C. Farquharson, S. F. Ahmed
Journal: Endocrine Reviews (2015)

Growth failure is frequently encountered in children with chronic inflammatory conditions like juvenile idiopathic arthritis, inflammatory bowel disease, and cystic fibrosis. Delayed puberty and attenuated pubertal growth spurt are often seen during adolescence. The underlying inflammatory state mediated by proinflammatory cytokines, prolonged use of glucocorticoid, and suboptimal nutrition contribute to growth failure and pubertal abnormalities. These factors can impair growth by their effects on the GH-IGF axis and also directly at the level of the growth plate via alterations in chondrogenesis and local growth factor signaling. Recent studies on the impact of cytokines and glucocorticoid on the growth plate further advanced our understanding of growth failure in chronic disease and provided a biological rationale of growth promotion. Targeting cytokines using biological therapy may lead to improvement of growth in some of these children, but approximately one-third continue to grow slowly. There is increasing evidence that the use of relatively high-dose recombinant human GH may lead to partial catch-up growth in chronic inflammatory conditions, although long-term follow-up data are currently limited. In this review, we comprehensively review the growth abnormalities in children with juvenile idiopathic arthritis, inflammatory bowel disease, and cystic fibrosis, systemic abnormalities of the GH-IGF axis, and growth plate perturbations. We also systematically reviewed all the current published studies of recombinant human GH in these conditions and discussed the role of recombinant human IGF-1.
Safety of proton therapy treatment for prostate cancer patients with unilateral hip replacements.
Authors: R. C. Nichols, B. S. Hoppe, M. W. Ho, H. Martinez, R. H. Henderson, R. Marcus, W. M. Mendenhall, J. A. Costa, C. R. Williams, N. P. Mendenhall
Journal: Journal of Clinical Oncology (2011)

100 Background: Determine the feasibility of proton therapy for prostate cancer patients who have undergone unilateral hip replacement. Methods: From January, 2007 to March, 2008 5 patients with localized (4) or locally recurrent (1) prostate cancer and previous unilateral hip replacement underwent hip avoiding proton therapy. The median target dose was 78 Cobalt Gray Equivalent (Range 74CGE to 82CGE). All patients were treated in the supine position without a rectal balloon. Median maximum (1cc) dose to the normal femoral head was 51.47CGE (Range 43.82CGE to 64.50CGE). All patients signed informed consent and were registered to either the IRB approved UFPTI PR01, PR02 or Outcome Tracking (OTP) Protocols. Results: With a median follow up of 28 (range 15 to 39) months, no patient experienced grade 2 or higher late rectal toxicity. No patient experienced grade 3 or higher late urinary toxicity. Two patients experienced grade 2 urinary toxicity by virtue of having been placed on medication (tamsulosin) for urinary obstructive symptoms. No patient has reported hip fracture, hip pain or other skeletal event in the normal hip. Conclusions: Our experience suggests that patients with unilateral hip replacements can be treated with hip avoiding proton therapy without an increased risk of urinary, rectal or skeletal complications. No significant financial relationships to disclose.
A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).
Authors: Y. Sun, Y. Shi, L. Zhang, X. Liu, C. Zhou, L. Zhang, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu, Y. Zhang, J. Chen, Y. Song, J. F. Feng, Y. Cheng, H. Zhang, Y. L. Wu, N. Xu, J. Zhou
Journal: Journal of Clinical Oncology (2011)

7522 Background: Icotinib is a potent and selective EGFR-TKI. Of 88 kinases profiled, Icotinib (Ic) powerfully inhibited EGFR and its 3 mutants, with no meaningful inhibition of the rest of kinases tested. This study was designed to show that Ic is not inferior to Gefitinib (Ge). Methods: Patients (Pts) with NSCLC progressed after one or two lines of chemotherapies were randomized to receive Ic (150mg Tid) or Ge (250mg Qd). The primary endpoint was PFS. The second endpoints were OS, ORR, TTP, QOL and tolerance. EGFR gene mutational analysis was performed by using DsX Scorpion ARMS. Results: From Feb 2009 to Nov 2010, 399 patients were randomized to receive either Ic (200) or Ge (199). Baseline characteristics were well balanced between the two arms . Ic demonstrated 35 day (d) median PFS extension compared to Ge (Ic vs. Ge: 137 d vs. 102, HR 0.84, 95% CI 0.67-1.05), reaching the primary objective of non-inferiority. With 49.4% maturity, OS was similar between Ic and Ge groups (median OS was 504 d and 531 d, respectively). Furthermore, ORR (Ic vs. Ge: 27.6% vs. 27.2%), DCR (75.4% vs. 74.9%), TTP (156 d vs. 111 d ) and QoL (101.4± 9.6 vs. 103.0± 19.1) were comparable between Ic and Ge groups. Adverse response rate in Ic group was 60.5%, which was significantly lower than that in Ge group (70.4%) (P=0.04). Specifically, 39.5% pts in Ic developed rash compared to 49.2% in Ge; 18.5% pts in Ic had diarrhea compared to 27.6% in Ge (P=0.03); 8.0% pts in Ic had elevated transaminase level compared to 12.6% in Ge. EGFR gene mutational analysis was performed for 132 pts. Mutations were identified in 66 pts (50%), among which 27 (40.9%) were in Ic and 39 (59.1%) were in Ge. The ORR and PFS in both Ic and Ge groups demonstrated significant differences between pts with mutations (M) and pts with the wild type gene (W). In the Ic group, M vs. W was 59.3% (16/27) vs. 5.1% (2/39) for ORR and 198 d vs. 70 d for PFS. In the Ge group it was 52.6% (20/39) vs. 3.7% (1/27) for ORR and 158 d vs. 76 d for PFS. Conclusions: This study demonstrated that Icotinib provides similar efficacy to Gefitinib, but with better tolerability, in NSCLC patients previously treated with one or two chemotherapy agents.
Adults without HIV infection hospitalised for tuberculosis – Clinical and drug sensitivity profiles
Authors: Nelson Teixeira, Teresa Carvalho, Isabel Gomes, José Agostinho Marques
Journal: European Respiratory Journal (2011)

Background:  Tuberculosis (TB) remains a major health problem and an important cause of hospitalisation for severity.   Aims:  To evaluate clinical and drug sensitivity profiles of patients without HIV infection hospitalised for TB.   Methods:  A retrospective study of adults admitted for TB to a tertiary hospital between 2007-2010, without HIV infection. Age, gender, clinical presentation,co-morbidities, radiological findings, diagnosis, drug sensitivity, therapy and outcome were evaluated.   Results:  The study included 207 patients, 18 to 89 years (mean 54,3 years).Of all, 69,6% had pulmonary TB, 10,1% pleural TB, 12,6% disseminated disease and 7,7% other forms. Co-morbidities were found in 136 patients. Main chest X-ray findings were unilateral (23,2%) or bilateral (17,9%) infiltrates, cavitation (14,5%) and pleural effusion (14,5%). M. tuberculosis was isolated in bronchial secretions in 125 cases, bronchial lavage in 46, gastric aspirate in 25, bronchoalveolar lavage in 23 and other products in 40. There was sensitivity to all first line TB drugs in 85,2% cases, mono-resistance in 10,9%, poly-resistance in 3,3% and multi-drug resistance in 0,5% (a extensively resistant case). Streptomycin (12,6%) and isoniazid (6,0%) had the highest resistance. Death occurred in 22 patients (10,6%), 86,4% had severe co-morbidities. The other patients were transferred to other hospitals (7) or discharged to out-patient TB clinics (178), 99 of them also referred to hospital consultations.   Conclusions:  In this group of patients co-morbidities were frequent, mortality was relevant and pulmonary TB was predominant as expected. TB drug sensitivity profile was not significantly different from ambulatory patients.
Calcitonin and vitamin D3 have high therapeutic potential for improving diabetic mandibular growth
Authors: Mona A Abbassy, Ippei Watari, Ahmed S Bakry, Takashi Ono, Ali H Hassan
Journal: International Journal of Oral Science (2015)

The goal of this study was to assess the effect of the intermittent combination of an antiresorptive agent (calcitonin) and an anabolic agent (vitamin D3) on treating the detrimental effects of Type 1 diabetes mellitus (DM) on mandibular bone formation and growth. Forty 3-week-old male Wistar rats were divided into four groups: the control group (normal rats), the control C+D group (normal rats injected with calcitonin and vitamin D3), the diabetic C+D group (diabetic rats injected with calcitonin and vitamin D3) and the diabetic group (uncontrolled diabetic rats). An experimental DM condition was induced in the male Wistar rats in the diabetic and diabetic C+D groups using a single dose of 60 mg·kg(-1) body weight of streptozotocin. Calcitonin and vitamin D3 were simultaneously injected in the rats of the control C+D and diabetic C+D groups. All rats were killed after 4 weeks, and the right mandibles were evaluated by micro-computed tomography and histomorphometric analysis. Diabetic rats showed a significant deterioration in bone quality and bone formation (diabetic group). By contrast, with the injection of calcitonin and vitamin D3, both bone parameters and bone formation significantly improved (diabetic C+D group) (P < 0.05). These findings suggest that these two hormones might potentially improve various bone properties.
Measurement of PD-L1 in melanoma: a quantitative antibody comparison
Authors: Joel C Sunshine, Sneha Berry, Jessica Esandrio, Haiying Xu, Aleksandra Ogurtsova, Toby Cornish, Evan J Lipson, Robert A Anders, Janis M Taube
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Immunohistochemical detection of PD-L1 may be used in the future as a biomarker to help select an immunotherapeutic regimen for patients with advanced melanoma. For example, patients whose tumors are PD-L1+ may receive anti-PD-1 monotherapy, and those whose tumors are PD-L1(-) may